Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer


I'm Interested

Trial ID: NCT04428788


The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Official Title

A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Must have histologically or cytologically confirmed adenocarcinoma of the prostate

   - Progressed on androgen deprivation therapy (ADT) and at least one prior secondary
   hormonal therapy approved for castration-resistant prostate cancer (CRPC)

   - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

   - Prior treatment with an androgen receptor (AR) degrader

   - Concurrent malignancy (present during screening) requiring treatment or history of
   prior malignancy active within 1 year prior to the first dose of IP

   - Clinically significant venous thromboembolism within 3 months prior to the first dose
   of IP

   - Any significant medical condition, such as uncontrolled infection, laboratory
   abnormality, or psychiatric illness

Other protocol-defined inclusion/exclusion criteria apply


drug: CC-94676

drug: CC1083611


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Aidan Keil O'Brien

New Trial Alerts

Receive email alerts when trials open to patients.